NR3C2 and diabetic kidney disease: This was shown in the Mineralocorticoid Receptor Antagonist Tolerability – diabetic nephropathy (ARTS-DN) study involving 1501 participants who were already receiving an ACEI or ARB (the mean age of the participants was 64.2 years, 37% had a UACR > 30 mg/mmol [> 265.49 mg/g] and 40% had an eGFR of 60 mL/min/1.73 m2 or lower).